In the Spotlight

Stroke damages not only neurons, but also the intricate networks of blood vessels and immune cells that shape recovery. In a new collaborative project, Daniel Razansky and Susanne Wegener aim to develop advanced imaging technologies […]

Akanksha Jain is the new Assistant Professor for Neural MorphoGenomics (tenure track) at the University of Zurich. This professorship was set up with a generous donation to ZNZ and support from the URPP “Adaptive Brain […]

Ed Boyden, pioneer of breakthrough brain technologies such as optogenetics and expansion microscopy, gave this year’s keynote speech at the ZNZ Symposium. In our interview, he shares his vision for brain research, reflects on the […]

Fred “Rusty” Gage from the Salk Institute and a pioneer in adult neurogenesis research, gave this year’s Konrad Akert Lecture in Zurich. In our interview, he speaks about the brain’s remarkable ability to generate new […]

Timothée Proix has received an SNF Starting Grant and will start this research at ETH Zurich in the summer. The grant aims to discover how our brains’ neuronal activity allows us to build complex sentences […]

Since its start in January 2021, a consortium of UZH research groups in the University Research Priority Program (URPP) “Adaptive Brain Circuits in Development and Learning” (AdaBD) has been working on unraveling the complexities of […]

Profs. Burkhard Becher, Christian Münz, & Tobias Derfuss recently obtained a Sinergia Grant of the SNSF. Multiple Sclerosis (MS) is a neurodegenerative autoimmune disease that is thought to be triggered by infectious diseases. Although the […]

Prof. Armin Curt and his team have been conducting a Europe-wide phase II clinical trial with NG-101, a recombinant human antibody. NG-101 neutralizes the membrane protein Nogo-A and thus promotes neural repair and functional recovery […]

Petra Schweinhardt and Jasmine Ho have recently received an SNF Sinergia Grant for their research project “Virtual Reality and Psychoplastogens: A Synergistic Approach for The Treatment of Chronic Pain”. The project is starting in spring […]

In January 2022, Hans-Georg Wirsching and his research group started their  project, “A phase Ib/II randomized drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma (GLUGLIO)”, which […]